Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COBRA: Carboplatin vs Olaparib in mCRPC
NCT04038502Phase 2Recruiting
- Sponsor
- VA Office of Research & Development
- Start
- Oct 2019
- Primary completion
- Aug 2027
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of carboplatin, olaparib in metastatic castration-resistant prostate cancer (mCRPC), sponsored by VA Office of Research & Development. Started Oct 2019; status: recruiting.
02
Drugs
carboplatinolaparib
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT04038502.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04038502.